SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is garnering significant attention amid heightened geopolitical interest in Greenland's rare earth deposits, driven by discussions around U.S. national security and securing critical mineral supply chains. The community is buzzing about upcoming high-level meetings between U.S., Danish, and Greenlandic officials, with many speculating on potential U.S. access to these strategic resources and anticipating a substantial upside for CRML's Tanbreez project. Despite recent volatility, investors are actively buying dips, holding strong conviction that CRML, with its large heavy rare earth element deposits, is a key player in reducing Western reliance on foreign suppliers.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is buzzing due to recent industry discussions highlighting advanced optical networking for AI and related strategic acquisitions, sparking speculation about its patented interposer technology. The community is intensely focused on POET's platform as a game-changer for hyperscale data centers, citing its efficiency and numerous partnerships with major industry players. Amidst a quiet period from management, investors are keenly anticipating news that could solidify its position at the forefront of the photonics revolution.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

Biodesix (BDSX) is trending after releasing strong preliminary fourth quarter and full-year 2025 results, which reported significant revenue growth and reaffirmed Adjusted EBITDA positivity. This announcement has ignited massive trading volume and a sharp increase in share price, leading to community discussion around a potential short squeeze and significant upside, alongside concerns about future dilution risks.

American Battery Technology Co. is a technology company, which engages in the development and marketing of lithium-ion batteries. Its projects include recycling plant, United States Advanced Battery Consortium (USABC), and Tonopah flats. The company was founded on October 6, 2011 and is headquartered in Reno, NV.

American Battery Technology Company

American Battery Technology Company is trending with significant bullish momentum, fueled by strong community sentiment surrounding its role in the U.S. critical minerals and battery recycling sector. Investors are actively discussing the impact of rising lithium prices and the company's strategic positioning amidst government initiatives like the G7 summit on critical metals, anticipating future growth and potential project milestones. Many believe ABAT is poised for substantial appreciation as demand for domestic battery materials heats up.

One Stop Systems, Inc. engages in the design, manufacture, and marketing of computing modules and systems targeting edge deployments. It deals with the design and manufacture of high-performance customized computer and flash arrays, in-flight entertainment, and connectivity and value-added reseller with minimal customization. It operates through the OSS and OSS Europe segments. The company was founded by Stephen D. Cooper and Mark Gunn in 1998 and is headquartered in Escondido, CA.

One Stop Systems Inc

One Stop Systems (OSS) is trending as the community anticipates significant growth from its specialized AI and edge computing solutions for the defense sector. Investors are particularly focused on a recent $1.2 million pre-production Army contract and the potential for a much larger $200 million sole-source award for situational awareness systems. The company's strategic move to divest Bressner Technology is seen as a key step to focus on higher-margin opportunities, fueling bullish sentiment around its undervalued status and tight float.

KOLANA is a koala-character meme coin that has been designed as the newest meme character token to join the Solana ecosystem. It’s a fun, community-driven token with no inherent value, created purely for those who want to participate in the Solana meme culture and become a part of the KOLANA community. While it doesn't offer utility or financial promises, it thrives on community engagement and decentralised fun.

KOLANA

KOLANA CRYPTO is gaining significant community attention, with many users expressing strong buying interest and advocating for early investment. Discussions highlight its perceived resilience and steady progress, noting KOLANA.X is holding structure and building quietly while market interest aligns and attention grows.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is trending as it moves to accelerate FDA submission for AXPAXLI's wet AMD treatment, aiming for approval based solely on year one SOL-1 Phase 3 data and potentially securing a coveted superiority label. This bold strategy has ignited a fervent community debate, with bulls anticipating a significant re-rating or buyout from major pharma seeking to protect their franchises, while skeptics raise concerns about recent share dilution and the trial's underlying design.

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is currently trending as the crypto community focuses on privacy tokens amidst broader market anticipation for regulatory clarity and potential Federal rate cuts. Investors are actively highlighting Dash's scarce supply and perceived undervaluation, with many expecting a significant rally comparable to its peer, Zcash, after a period of price consolidation.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to recent high-grade silver drill results and anticipation for an updated resource estimate in Q1 2026, alongside continued significant investment from Eric Sprott. The community is actively debating the company's vast undeveloped potential amidst a global silver shortage and increasing industrial demand, while also considering the speculative nature and potential for future dilution. This places HYMC at the forefront of discussions regarding domestic precious metal resources in a tightening market.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is trending due to a wave of analyst downgrades, citing concerns over slowing bookings and margin pressures from significant investments in AI and safety features. Heightened regulatory scrutiny and lawsuits from multiple states regarding child safety on the platform, alongside new mandatory age verification for chat, are sparking considerable community debate about user experience and privacy. Investors are actively discussing technical support levels and the platform's ability to maintain its user base amidst these evolving challenges and public concerns.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co.

JPMorgan Chase & Co. reduced their target price on Neurocrine Biosciences from $179.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday...

Neurocrine Biosciences, Inc. $NBIX Stock Holdings Increased by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 86.7% in the 3rd quarter, according to the company in its most...

Cerity Partners LLC Acquires 44,852 Shares of Neurocrine Biosciences, Inc. $NBIX

Cerity Partners LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 76.3% during the third quarter, according to the company in its most recent filing with...

Neurocrine Biosciences (NASDAQ:NBIX) Price Target Lowered to $169.00 at Truist Financial

Truist Financial lowered their price objective on shares of Neurocrine Biosciences from $172.00 to $169.00 and set a "buy" rating for the company in a research report on Thursday...

Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO...

<ul class="summary-bullets"><li>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with congenital adrenal hyperplasia caused by 21-hydroxylase deficiency.</li><li>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates."</li><li>Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</li></ul><p>Crinetics Pharmaceuticals, Inc. (CRNX) said on Monday that its experimental drug Atumelnant yielded positive results in the fourth cohort of a congenital adrenal hyperplasia trial (CAH), sending shares up 3% in Monday’s mid-day trading. &nbsp;</p><p>Atumelnant is a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic congenital adrenal hyperplasia as well as adrenocorticotropic hormone-dependent Cushing’s syndrome.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2026/01/05/3212693/0/en/Crinetics-Announces-Strong-PALSONIFY-Launch-Execution-and-Positive-Results-for-Concurrent-Androstenedione-Lowering-and-Glucocorticoid-Dose-Reduction-in-Phase-2-Trial-of-Atumelnant-.html?_gl=1*dclqt*_up*MQ..*_ga*MTQ5MTU3MjU2MS4xNzY3NjMzMDE2*_ga_ERWPGTJ5X8*czE3Njc2MzMwMTUkbzEkZzAkdDE3Njc2MzMwMjIkajUzJGwwJGgw">said</a> that treatment with Atumelnant resulted in rapid, sustained lowering of androstenedione in all eight patients that completed the fourth cohort of the mid-stage trial.</p><p>Shares of Neurocrine Biosciences (NBIX), whose Crenessity drug is approved for CAH, fell by 3% following the rival’s update.</p><h2 class="st-heading-2">Trial Results</h2><p>The trial was aimed at evaluating the efficacy, safety, and pharmacokinetics of Atumelnant when administered for 12 weeks in people with CAH caused by 21-hydroxylase deficiency. CAH is a group of genetic disorders affecting the adrenal glands, preventing them from producing enough cortisol and aldosterone. It leads to issues with energy, blood sugar, blood pressure, salt/water balance, and sexual development.</p><p>The drug was observed to be well-tolerated, with no serious adverse events and no treatment-related severe adverse events, the company added.</p><h2 class="st-heading-2">Positive Feedback For Palsonify</h2><p>Separately, Crinetics also reported unaudited and preliminary net product revenue of over $5 million in fourth-quarter 2025 for its new drug Palsonify in the U.S.</p><p>Palsonify was approved by the U.S. Food and Drug Administration (FDA) on September 25 for the first-line treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.</p><p>The company noted that feedback from patients, physicians and payers have been positive thus far.</p><h2 class="st-heading-2">Expert Take</h2><p>Following the announcement, Evercore ISI raised the firm's price target on Crinetics to $90 from $80 and keeps an Outperform rating on the shares following what the firm views as "very strong updates," as per TheFly.</p><p>The firm believes the Atumelnant update will be "much more impactful" for the stock today as it contends that Crinetics "again looks to comfortably have 2 blockbuster," high odds of success products and more in earlier development.</p><p>RBC Capital analyst Brian Abrahams noted that the data looked very supportive of the drug's ability to be a potential competitor that could reach the CAH market within the next few years, according to TheFly. However, the firm believes comparing the dataset to Neurocrine's phase III study data is limited, primarily due to the differences in patient population. Overall, RBC notes that while competitor data reaffirms a potential emerging player in the CAH space, this was already well known, patient stickiness may shield Crenessity from future competition. Even with conservative estimates, it sees Crenessity contributing $1.1 billion to Neurocrine's revenue stream in the U.S. market alone.</p><p>RBC added that it would be a buyer of Outperform-rated Neurocrine on weakness.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around CRNX stock jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels at the time of writing. Sentiment around <a href="https://stocktwits.com/symbol/NBIX">NBIX stock</a> stayed within the ‘bearish’ territory in the same time.</p><p><a href="https://stocktwits.com/symbol/CRNX">CRNX stock</a> has dropped 5% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/general-motors-q4-deliveries-dive-on-lower-ev-sales/cmxMtAZR4RJ">General Motors Q4 Deliveries Dive On Lower EV Sales — Automaker Looks To Next-Generation Bolt EV For Bounceback</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration, the Crinetics Pharmaceuticals logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.

Equity

Crinetics Pharmaceuticals said that treatment with experimental drug Atumelnant resulted in rapid, sustained lowering of androstenedione in eight patients that completed the fourth cohort of a congenital adrenal hyperplasia trial.


Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Down - Here's Why

Neurocrine Biosciences (NASDAQ:NBIX) Shares Gap Down - Here's What Happened...

Stanley Laman Group Ltd. Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX

Stanley Laman Group Ltd. trimmed its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 40.4% during the third quarter, according to the company in its most recent 13F filing...

Merit Financial Group LLC Boosts Stock Position in Neurocrine Biosciences, Inc. $NBIX

Merit Financial Group LLC boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 101.3% during the third quarter, according to the company in its most recent...

Braun Stacey Associates Inc. Has $25.69 Million Stock Position in Neurocrine Biosciences, Inc. $NBIX

Braun Stacey Associates Inc. boosted its position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 7.4% in the 3rd quarter, according to its most recent filing with the...

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Neurocrine Biosciences, Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Current Price	$132.66
Prev Close	$135.79
Open	$135.21
Dividend Yield	0.00%
50-Day Moving Average	$145.83
Beta	0.71
Avg. Volume	952,959.59
PE Ratio	31.68

52-Week High	$160.18
52-Week Low	$84.23
Market Capitalization	$13.54B
EPS (Annual)	$3.29
Price to Book	4.40
Revenue Per Employee	$1.31M
Enterprise Value/EBITDA	N/A

NBIX
Neurocrine Biosciences, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NBIX News

NBIXNeurocrine Biosciences, Inc.